13/06/2022
Alectinib was approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small-cell lung cancer (NSCLC).
https://rxlibra.com/products
We RxLibra Development are
Consulting services, Formulation manufacturing & Medicine exporters. RxLibra Development Laos Co., LTD
19 Saylom Rd,
Vientiane
0100
| Monday | 09:00 - 17:00 |
| Tuesday | 09:00 - 17:00 |
| Wednesday | 09:00 - 17:00 |
| Thursday | 09:00 - 17:00 |
| Friday | 09:00 - 18:00 |
Be the first to know and let us send you an email when Phaly RxLibra posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Phaly RxLibra: